Therapy hinders AIDS virus from evolving drug resistance, Hopkins researchers find

A team of scientists from Johns Hopkins Children's Center and two other institutions have found that low levels of HIV-1 virus in the blood of children and adults undergoing a common combination drug therapy does not necessarily indicate the virus is becoming resistant to these life-prolonging medications.

In the first study to show a low level of viral activity in children using the therapy, called HAART (highly active anti-retroviral therapy), a team led by Children's Center infectious disease researcher Deborah Persaud, M.D., says that bloodstream signatures of HIV-1 revealed no genetic signs that the virus was developing resistance. The finding, published in this week's Journal of the American Medical Association, has implications for the design and future treatment strategies in fighting the onset of AIDS.

"Going into the study, we thought it was possible that even low levels of virus activity could result in the evolution of resistance to HAART drugs," Persaud says. "But both the children and adults in our study showed that the therapy is working."

The report also shows that occasional increases in apparent virus activity, called "blips," do not necessarily indicate the virus is resisting the protease inhibitors and anti-retroviral drugs that make up HAART.

From the blood samples of 20 study participants, all of whom had been on HAART at least 25 months, the research team looked for the unique genetic signature left by very low levels of HIV-1, a virus that inserts itself into the human genome and begins replicating as though it were any other set of human genes.

The researchers compared each viral genetic sequence to other viral sequences from the same patient, to other patients' viral sequences and to sequences that represent drug-resistant viruses. The researchers found that viral replication and mutation had remained suppressed by HAART. Two of the 20 study participants, who responded less than optimally to HAART

Contact: David Bricker
Johns Hopkins Medical Institutions

Page: 1 2

Related biology news :

1. 1st International Conference on Cell Therapy for Cardiovascular Disease
2. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
3. Braunschweig Prize 2003 for Molecular Cancer Therapy
4. Alliance for Cancer Gene Therapy announces $1.5 million in national grants to young investigators
5. New research on safety of intracoronary delivery of adenovector reported in cover story of Molecular Therapy
6. Invitation To Cover: American Society Of Gene Therapy Meeting
7. Gene Therapy For Pain
8. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy
9. Shock Therapy Exceeds Expectations In Cleaning Up Contaminated Soils
10. Penn Researchers Develop Gene Therapy Technique That Reverses Muscle Membrane Weakness In Muscular Dystrophy Variant
11. University Of Pittsburgh Involved In First Successful Example Of Gene Therapy For Pain Control

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: